Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Niloo Boroun · Director of International Policy, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Kasondra White · Acting Director General, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Karim Bardeesy · Parliamentary Secretary to the Minister of Industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Philip Jennings · Deputy Minister of Innovation, Science and Economic Development Canada (ISED), Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Michael DeJong · Assistant Secretary, Regulatory Affairs Sector, Treasury Board Secretariat, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Joss Reimer · Chief Public Health Officer, Public Health Agency of Canada (PHAC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Justine Frame · Senior Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Yash Nanda · Senior Policy Advisor, Prime Minister's Office, Prime Minister's Office (PMO)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Ali Ehsassi · Parliamentary Secretary to the President of the King’s Privy Council for Canada and Minister responsible for Canada–U.S. Trade, Privy Council Office (PCO)
Free trade agreements as they relate to the biopharmaceutical industryRead more
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
and 6 moreShow fewer
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industryRead more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
and 3 moreShow fewer
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Celia Lourenco · Associate Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Sara O’Connor · Director General, Health Canada (HC)
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical productsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.